Donor lymphocyte infusions to displace residual host hematopoietic cells after allogeneic bone marrow transplantation for β-thalassemia major

Journal of Pediatric Hematology/Oncology

Volumn 20, Issue 2, 1998, Pages 145-148

  Aker, Memet ^a   Kapelushnik, Joseph ^a   Pugatsch, Thea ^a   Naparstek, Elizabeth ^a   Ben Neria, Susana ^a   Yehuda, Orly ^a   Amar, Avraham ^a   Nagler, Arnon ^a   Slavin, Shimon ^a   Or, Reuven ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

thalassemia major; Bone marrow transplantation; Donor lymphocyte infusion

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G2B; THIOTEPA;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CASE REPORT; CHIMERA; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC CELL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE; MALE; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PRIORITY JOURNAL; RELAPSE; STEROID THERAPY; SUBCUTANEOUS DRUG ADMINISTRATION; THALASSEMIA MAJOR; TREATMENT OUTCOME;

BETA-THALASSEMIA; BONE MARROW TRANSPLANTATION; CHILD, PRESCHOOL; CHIMERA; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELLS; HUMANS; LYMPHOCYTE TRANSFUSION; MALE;

EID: 0031924653     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199803000-00011     Document Type: Article

References (18)

1. Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med 1990;322: 417-21.
2. Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med 1993;329:840-4.
3. Lucarelli G, Clife RA, Galimberti M, et al. Marrow transplantation for patients with thalassemia: results in class 3 patients. Blood 1996;87:2082-8.
4. Or R, Mehta J, Kapelushnik J, et al. Total lymphoid irradiation, antilymphocyte globulin and Campath 1-G for immunosuppression prior to bone marrow transplantation for aplastic anemia after repeated graft rejection. Bone Marrow Transplant 1994;13:97-9.
5. Or R, Naparstek E, Cividalli G, et al. Bone marrow transplantation in β-thalassemia major: the Israeli experience. Hemoglobin 1988;12: 609-14.
6. Waldmann H, Polliack A, Hale G, et al. Elimination of graft-versus-host disease by in vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 1984;ii:483-6.
7. Mackinon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-host leukemia responses from graft-versus-host disease. Blood 1995;86:1261-8.
8. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15:433-44.
9. Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462-5.
10. Kapelushnik J, Nagler A, Or R, et al. Activated allogeneic cell therapy (allo-ACT) for relapsed chronic myelogenous leukemia (CML) refractory to buffy coat transfusions post-allogeneic bone marrow transplantation. Bone Marrow Transplant 1996;18:1153-6.
11. Papadopoulos EB, Ladanyi N, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994;330:1185-91.
12. Pugatsch T, Oppenheim A, Slavin S. Improved single-step PCR assay for sex identification post-allogeneic sex-mismatched BMT. Bone Marrow Transplant 1996;17:273-5.
13. Kapelushnik J, Or R, Filon D, et al. Analysis of β-globin mutations shows stable mixed chimerism in patients with thalassemia after bone marrow transplantation. Blood 1995;86:3241-6.
14. Nesci S, Manna M, Andreani M, et al. Mixed chimerism in thalassemic patients after bone marrow transplantation. Bone Marrow Transplant 1992;10:143-6.
15. Bertheas MF, Lafage M, Levy P, et al. Influence of mixed chimerism on the results of allogeneic bone marrow transplantation for leukemia. Blood 1991;78:3103-6.
16. Frassoni F, Strada P, Sessarego M, et al. Mixed chimerism after allogeneic marrow transplantation for leukemia: Correlation with dose of total body irradiation and graft-versus-host disease. Bone Marrow Transplant 1990;5:235-40.
17. Drobyski WR, Roth MS, Thibodeau SN, et al. Molecular remission occurring after donor leukocyte infusions for the treatment of relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Bone Marrow Transplant 1992;10:301-4.
18. Drobyski WR, Keever CA, Roth MS, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood 1993;82:2310-8.